

Remarks

Claims 1, 2, 3, 4, 5, 6 and 8 are pending. Claims 1, 5 and 8 have been amended. Claims 7, 9 and 10-17 have been cancelled.


Election/Restriction

Applicants wish to provisionally elect without traverse Group I1, which are claims 1-9, drawn to a method of treating myeloma. Independent claim 1 has been amended to define methods of treating a warm-blooded animal having myeloma comprising epothilone B. Therefore, the species elected is epothilone B. Applicants reserve the right to file a divisional application pertaining to the subject matter in Group II.

Entry of this Response is respectfully requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Oona A. Manzari
Attorney for Applicants
Reg. No. 48,152

D a t e: 10/17/19